IN8bio (INAB) Competitors $0.25 +0.01 (+2.14%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INAB vs. GNTA, THTX, PEPG, PYRGF, INZY, IKNA, CLLS, CLSD, ALTS, and IMABShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Genenta Science (GNTA), Theratechnologies (THTX), PepGen (PEPG), PyroGenesis Canada (PYRGF), Inozyme Pharma (INZY), Ikena Oncology (IKNA), Cellectis (CLLS), Clearside Biomedical (CLSD), Janone (ALTS), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Genenta Science Theratechnologies PepGen PyroGenesis Canada Inozyme Pharma Ikena Oncology Cellectis Clearside Biomedical Janone I-Mab IN8bio (NASDAQ:INAB) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Do institutionals & insiders have more ownership in INAB or GNTA? 92.1% of IN8bio shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 15.5% of IN8bio shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is INAB or GNTA more profitable? Genenta Science's return on equity of 0.00% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -197.15% -130.48% Genenta Science N/A N/A N/A Which has stronger valuation & earnings, INAB or GNTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.01M-$0.75-0.33Genenta ScienceN/AN/A-$12.60MN/AN/A Which has more volatility & risk, INAB or GNTA? IN8bio has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Does the media refer more to INAB or GNTA? In the previous week, IN8bio had 2 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for IN8bio and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.89 beat IN8bio's score of 0.47 indicating that Genenta Science is being referred to more favorably in the news media. Company Overall Sentiment IN8bio Neutral Genenta Science Very Positive Do analysts rate INAB or GNTA? IN8bio presently has a consensus price target of $7.75, suggesting a potential upside of 3,050.41%. Genenta Science has a consensus price target of $25.00, suggesting a potential upside of 484.80%. Given IN8bio's higher probable upside, equities research analysts clearly believe IN8bio is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer INAB or GNTA? IN8bio received 18 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 73.53% of users gave IN8bio an outperform vote. CompanyUnderperformOutperformIN8bioOutperform Votes2573.53% Underperform Votes926.47% Genenta ScienceOutperform Votes787.50% Underperform Votes112.50% SummaryGenenta Science beats IN8bio on 7 of the 12 factors compared between the two stocks. Remove Ads Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.67M$3.05B$5.64B$8.09BDividend YieldN/A1.47%4.89%4.04%P/E Ratio-0.3228.0523.8419.00Price / SalesN/A370.02381.26120.29Price / CashN/A168.6838.0534.62Price / Book0.423.446.874.23Net Income-$30.01M-$71.72M$3.19B$246.59M7 Day Performance-8.21%-2.74%-2.17%-2.79%1 Month Performance-15.43%-9.55%-7.20%-8.72%1 Year Performance-80.63%-22.82%8.84%1.39% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.0781 of 5 stars$0.25+2.1%$7.75+3,025.0%-80.9%$19.75MN/A-0.3220Upcoming EarningsGNTAGenenta Science3.0483 of 5 stars$3.80flat$25.00+557.9%-2.8%$69.50MN/A0.007Positive NewsTHTXTheratechnologiesN/A$1.50-1.3%N/A+24.6%$68.97M$85.87M-15.00140News CoveragePEPGPepGen2.8742 of 5 stars$2.09-9.5%$10.33+394.4%-82.3%$68.33MN/A-0.7030Short Interest ↑PYRGFPyroGenesis CanadaN/A$0.37-3.9%N/A+11.5%$68.13M$9.14M-6.1790Gap UpHigh Trading VolumeINZYInozyme Pharma2.9399 of 5 stars$1.06-7.8%$17.78+1,577.1%-81.5%$68.09MN/A-0.6850Analyst ForecastNews CoverageIKNAIkena Oncology3.0233 of 5 stars$1.41-2.1%$3.00+112.8%-5.5%$68.04M$659,000.00-1.1570Earnings ReportPositive NewsCLLSCellectis3.2276 of 5 stars$1.22-2.8%$7.00+473.8%-48.6%$67.81M$29.07M-0.94290CLSDClearside Biomedical2.8477 of 5 stars$0.88-5.2%$5.33+506.2%-57.8%$66.73M$7.70M-1.9630ALTSJanoneN/A$4.72-8.0%N/AN/A$66.41M$7.11M0.00170Short Interest ↑Positive NewsIMABI-Mab2.7506 of 5 stars$0.81-5.2%$8.00+885.2%-55.6%$66.18M$3.27M0.00380Upcoming Earnings Remove Ads Related Companies and Tools Related Companies GNTA Competitors THTX Competitors PEPG Competitors PYRGF Competitors INZY Competitors IKNA Competitors CLLS Competitors CLSD Competitors ALTS Competitors IMAB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INAB) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
